Global Antibody Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration (Intravenous, Subcutaneous, and Others), By Format, By Source, By End User, By Disease Areas, By Regional Outlook and Forecast, 2023 - 2030

Global Antibody Therapeutics Market Size, Share & Trends Analysis Report By Route of Administration (Intravenous, Subcutaneous, and Others), By Format, By Source, By End User, By Disease Areas, By Regional Outlook and Forecast, 2023 - 2030


The Global Antibody Therapeutics Market size is expected to reach $631.3 billion by 2030, rising at a market growth of 14.4% CAGR during the forecast period.

Antibody therapeutics are explored to prevent and treat respiratory infections, like those caused by respiratory syncytial virus (RSV), influenza, and other respiratory pathogens. Thus, the Infectious Diseases segment acquired $27,652.5 million in 2022. Monoclonal antibodies can provide passive immunity and reduce the risk of severe disease. It offers a form of passive immunization, providing immediate protection against infectious agents. This is particularly important in situations where there is a need for rapid intervention, such as in the case of post-exposure prophylaxis. Some of the factors impacting the market are technological advancements in antibody engineering, increasing number of senior citizens and high development costs of antibody therapeutics.

Advances in antibody engineering technologies, including antibody-drug conjugates (ADCs), Fc engineering, and next-generation sequencing, enhance the properties and performance of antibody therapeutics. These technological advancements contribute to developing more potent, specific, and well-tolerated antibody drugs. Single-cell antibody technologies enable the isolation and characterization of individual B cells, allowing for the identification of rare and high-affinity antibodies. This approach is particularly valuable when traditional hybridoma or phage display methods may not capture the full diversity of the immune response. Single-cell antibody technologies contribute to developing antibodies with enhanced specificity and functionality. Additionally, the aging process is associated with an elevated risk of various age-related diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Antibody therapeutics, with their targeted and precision-based mechanisms, are well-suited for addressing the underlying causes of these diseases. As per the World Health Organization (WHO), one in six people will be 60 or older by 2030. The number of people 60 and older in the world will increase from 1 billion in 2020 to 1.4 billion in 2050. By 2050, there will be 2.1 billion people in the world who are 60 or older. It is anticipated that there will be 426 million persons 80 or older by 2050. This preference for targeted therapies aligns with the growing awareness of minimizing side effects in older populations. Increasing number of senior citizens has been a pivotal factor in driving the growth of the market.

Further, the pandemic highlighted vulnerabilities in global supply chains, affecting pharmaceutical product development and distribution, particularly antibody therapeutics. Disruptions in the supply chain, shortages of critical raw materials, and logistical challenges impacted the manufacturing and delivery of antibody drugs. Monoclonal antibodies were also deployed for prophylactic use in individuals at high risk of exposure to COVID-19, like those with underlying health conditions or individuals in close contact with infected individuals. The success of mRNA vaccines, such as those developed by Pfizer-BioNTech and Moderna, shifted attention towards nucleic acid-based therapies. While there was a heightened focus on infectious disease research, including antibody therapeutics for COVID-19, other therapeutic areas experienced shifts in priorities and resource allocation. Thus, the COVID-19 pandemic had a moderate effect on the market.

However, the research and development of antibody therapeutics involves substantial costs, including preclinical studies, clinical trials, and manufacturing expenses. The high investment required can pose a barrier, especially for smaller biotech companies, hindering their ability to bring novel antibodies to market. The financial burden associated with antibody development may lead to a focus on well-established targets and therapeutic areas, potentially limiting exploration in areas with significant unmet medical needs. This reduced innovation and diversity in the development pipeline can hinder the discovery of breakthrough therapies. High development costs of antibody therapeutics are a significant challenge that hampers the growth of the market.

By Route of Administration Outlook

On the basis of route of administration, the market is divided into intravenous, subcutaneous, and others. In 2022, the intravenous segment dominated the market with maximum revenue share. Intravenous administration ensures rapid and complete bioavailability of antibody therapeutics. This route allows the drug to enter the bloodstream directly, avoiding barriers such as the gastrointestinal tract, which can impact absorption rates. Intravenous delivery allows for precise dosing and control over the rate of administration. Healthcare professionals can carefully regulate the infusion rate to achieve therapeutic levels in the bloodstream, optimizing the efficacy of antibody therapeutics. Intravenous administration provides an immediate onset of action for antibody therapeutics. This is crucial when rapid therapeutic effects are needed, such as in treating acute conditions or emergencies.

By Format Outlook

By format, the market is categorized into monoclonal antibody, polyclonal antibody therapy, bispecific antibody, antibody fragment, and others. The antibody fragment segment procured a promising growth rate in the market in 2022. Antibody fragments typically exhibit faster clearance from the circulatory system compared to full-length antibodies. This rapid clearance can be beneficial when a quick onset of action or a shorter half-life is desired, providing greater control over the timing and duration of the therapeutic effect. Antibody fragments are widely used in diagnostic imaging applications. Their smaller size allows for rapid clearance from non-target tissues, improving imaging contrast. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) frequently use radiolabeled antibody fragments. Antibody fragments are explored for therapeutic applications in autoimmune diseases, where targeted and localized immunosuppression is desired.

By Source Outlook

By source, the market is segmented into human, humanized, chimeric, and others. In 2022, the human segment registered the maximum revenue share in the market. Human innovation and technological advancements, such as genetic engineering, monoclonal antibody production, and novel drug delivery systems, contribute to creating more effective and targeted antibody therapies. Human efforts in educating healthcare professionals, patients, and the public about the benefits and availability of antibody therapeutics contribute to their acceptance and utilization. Humans participate in clinical trials to test the efficacy and safety of antibody therapeutics. Their participation generates valuable data that inform the development process and regulatory approvals.

By End User Outlook

Based on end user, the market is fragmented into hospitals, long-term care facilities, and others. The long-term care facilities segment covered a considerable revenue share in the market in 2022. Long-term care facilities often cater to an aging population, which is more susceptible to conditions that may benefit from antibody therapeutics, including certain types of cancer, rheumatoid arthritis, and neurodegenerative disorders. The use of antibody therapeutics in long-term care facilities can reduce hospitalization rates. This is particularly important for residents who may have difficulty traveling to hospitals or are at higher risk of complications from hospital stays. Antibody therapeutics, particularly monoclonal antibodies, can prevent and manage infections. These treatments can support overall health maintenance in long-term care settings where people may be more susceptible to infections.

By Disease Areas Outlook

Based on disease areas, the market is classified into autoimmune & inflammatory diseases, oncology, hematology, infectious diseases, osteology, immunology, neurology, and others. The oncology segment procured a promising growth rate in the market in 2022. Antibody therapeutics are often combined with other cancer treatments, such as chemotherapy, targeted therapies, and radiation therapy. Combinatorial approaches aim to maximize treatment efficacy and address multiple aspects of cancer biology. Antibody therapeutics have proven effective in treating hematologic cancers, including various lymphomas and leukemias. Monoclonal antibodies, such as rituximab and alemtuzumab, target specific markers on cancer cells, leading to improved outcomes. Radioimmunotherapy involves antibodies labeled with radioactive isotopes to selectively deliver radiation to cancer cells. Ibritumomab, tiuxetan, and tositumomab are examples of radioimmunotherapy used in certain lymphomas.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region led the market by generating the highest revenue share. North America, particularly the United States, is home to a vibrant and well-established pharmaceutical research and development ecosystem. North America is a global hub for clinical trials, providing a robust infrastructure for conducting large-scale and diverse studies. The North American population has a relatively high prevalence of autoimmune diseases, like rheumatoid arthritis, psoriasis, and inflammatory bowel diseases.

The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include F. Hoffmann-La Roche Ltd, AbbVie, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Merck KGaA, Bristol Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Novartis AG, Biogen, Inc. and Amgen, Inc.

Strategies Deployed in Antibody Therapeutics market.

Dec-2023: AbbVie, Inc. came into partnership with BigHat Biosciences, a US-based biotechnology research company. Through this partnership, AbbVie, Inc. would explore and advance the development of cutting-edge therapeutic antibodies in the fields of oncology and neuroscience."

Dec-2023: AbbVie, Inc. took over Cerevel Therapeutics Hldg, biotech company in United States. Through this acquisition, AbbVie, Inc. would enhance its neuroscience portfolio.

Feb-2023: F. Hoffmann-La Roche Ltd came into partnership with Janssen Biotech Inc., a US-based pharmaceutical company. Through this partnership, F. Hoffmann-La Roche Ltd would enhance and develop companion diagnostics for targeted therapies. Additionally, this initiative strengthens the connection between diagnostics and treatments, fostering progress in precision healthcare.

Dec-2022: Merck KGaA came into partnership with Mersana Therapeutics, a biotech company in the United States. Through this partnership, Merck KGaA would develop innovative immunostimulatory antibody-drug conjugates.

Oct-2022: F. Hoffmann-La Roche Ltd came into partnership with Atea Pharmaceuticals, a US-based biotechnology research company. Through this partnership, F. Hoffmann-La Roche Ltd would create a prospective oral therapy for individuals with covid-19. Additionally, this therapy enables extensive production and promotes widespread patient availability.

Oct-2022: F. Hoffmann-La Roche Ltd introduced 'SARS-CoV-2 Rapid Antibody Test 2.0'. The SARS-CoV-2 Rapid Antibody Test 2.0 provides wider applicability than its initial design and now encompasses individuals who have been vaccinated.

Apr-2020: Johnson & Johnson came into partnership with Catalent, Inc., a US-based pharmaceutical manufacturing company. Through this partnership, Johnson & Johnson would enhance its manufacturing capability and lead vaccine candidates for COVID-19.

Mar-2019: Bristol Myers Squibb Company took over Celgene Corporation, a pharmaceutical company in the United States. Through this acquisition, Bristol Myers Squibb Company would establish a biopharmaceutical company.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration
  • Intravenous
  • Subcutaneous
  • Others
By Format
  • Monoclonal Antibody
  • Polyclonal Antibody Therapy
  • Bispecific Antibody
  • Antibody fragment & Others
By Source
  • Human
  • Humanized
  • Chimeric
By End User
  • Hospitals
  • Long-term care facilities
  • Other
By Disease Areas
  • Autoimmune & Inflammatory Diseases
  • Neurology
  • Osteology
  • Hematology
  • Oncology
  • Infectious Diseases
  • Immunology
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • F. Hoffmann-La Roche Ltd
  • AbbVie, Inc.
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Merck KGaA
  • Bristol Myers Squibb Company
  • AstraZeneca PLC
  • Sanofi S.A.
  • Novartis AG
  • Biogen, Inc.
  • Amgen, Inc.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Antibody Therapeutics Market, by Route of Administration
1.4.2 Global Antibody Therapeutics Market, by Format
1.4.3 Global Antibody Therapeutics Market, by Source
1.4.4 Global Antibody Therapeutics Market, by End User
1.4.5 Global Antibody Therapeutics Market, by Disease Areas
1.4.6 Global Antibody Therapeutics Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies Deployed in Antibody Therapeutics market.
Chapter 5. Global Antibody Therapeutics Market by Route of Administration
5.1 Global Intravenous Market by Region
5.2 Global Subcutaneous Market by Region
5.3 Global Others Market by Region
Chapter 6. Global Antibody Therapeutics Market by Format
6.1 Global Monoclonal Antibody Market by Region
6.2 Global Polyclonal Antibody Therapy Market by Region
6.3 Global Bispecific Antibody Market by Region
6.4 Global Antibody fragment & Others Market by Region
Chapter 7. Global Antibody Therapeutics Market by Source
7.1 Global Human Market by Region
7.2 Global Humanized Market by Region
7.3 Global Chimeric Market by Region
7.4 Global Others Market by Region
Chapter 8. Global Antibody Therapeutics Market by End User
8.1 Global Hospitals Market by Region
8.2 Global Long-term care facilities Market by Region
8.3 Global Others Market by Region
Chapter 9. Global Antibody Therapeutics Market by Disease Areas
9.1 Global Autoimmune & Inflammatory Diseases Market by Region
9.2 Global Neurology Market by Region
9.3 Global Osteology Market by Region
9.4 Global Hematology Market by Region
9.5 Global Oncology Market by Region
9.6 Global Infectious Diseases Market by Region
9.7 Global Immunology Market by Region
9.8 Global Others Market by Region
Chapter 10. Global Antibody Therapeutics Market by Region
10.1 North America Antibody Therapeutics Market
10.1.1 North America Antibody Therapeutics Market by Route of Administration
10.1.1.1 North America Intravenous Market by Country
10.1.1.2 North America Subcutaneous Market by Country
10.1.1.3 North America Others Market by Country
10.1.2 North America Antibody Therapeutics Market by Format
10.1.2.1 North America Monoclonal Antibody Market by Country
10.1.2.2 North America Polyclonal Antibody Therapy Market by Country
10.1.2.3 North America Bispecific Antibody Market by Country
10.1.2.4 North America Antibody fragment & Others Market by Country
10.1.3 North America Antibody Therapeutics Market by Source
10.1.3.1 North America Human Market by Country
10.1.3.2 North America Humanized Market by Country
10.1.3.3 North America Chimeric Market by Country
10.1.3.4 North America Others Market by Country
10.1.4 North America Antibody Therapeutics Market by End User
10.1.4.1 North America Hospitals Market by Country
10.1.4.2 North America Long-term care facilities Market by Country
10.1.4.3 North America Others Market by Country
10.1.5 North America Antibody Therapeutics Market by Disease Areas
10.1.5.1 North America Autoimmune & Inflammatory Diseases Market by Country
10.1.5.2 North America Neurology Market by Country
10.1.5.3 North America Osteology Market by Country
10.1.5.4 North America Hematology Market by Country
10.1.5.5 North America Oncology Market by Country
10.1.5.6 North America Infectious Diseases Market by Country
10.1.5.7 North America Immunology Market by Country
10.1.5.8 North America Others Market by Country
10.1.6 North America Antibody Therapeutics Market by Country
10.1.6.1 US Antibody Therapeutics Market
10.1.6.1.1 US Antibody Therapeutics Market by Route of Administration
10.1.6.1.2 US Antibody Therapeutics Market by Format
10.1.6.1.3 US Antibody Therapeutics Market by Source
10.1.6.1.4 US Antibody Therapeutics Market by End User
10.1.6.1.5 US Antibody Therapeutics Market by Disease Areas
10.1.6.2 Canada Antibody Therapeutics Market
10.1.6.2.1 Canada Antibody Therapeutics Market by Route of Administration
10.1.6.2.2 Canada Antibody Therapeutics Market by Format
10.1.6.2.3 Canada Antibody Therapeutics Market by Source
10.1.6.2.4 Canada Antibody Therapeutics Market by End User
10.1.6.2.5 Canada Antibody Therapeutics Market by Disease Areas
10.1.6.3 Mexico Antibody Therapeutics Market
10.1.6.3.1 Mexico Antibody Therapeutics Market by Route of Administration
10.1.6.3.2 Mexico Antibody Therapeutics Market by Format
10.1.6.3.3 Mexico Antibody Therapeutics Market by Source
10.1.6.3.4 Mexico Antibody Therapeutics Market by End User
10.1.6.3.5 Mexico Antibody Therapeutics Market by Disease Areas
10.1.6.4 Rest of North America Antibody Therapeutics Market
10.1.6.4.1 Rest of North America Antibody Therapeutics Market by Route of Administration
10.1.6.4.2 Rest of North America Antibody Therapeutics Market by Format
10.1.6.4.3 Rest of North America Antibody Therapeutics Market by Source
10.1.6.4.4 Rest of North America Antibody Therapeutics Market by End User
10.1.6.4.5 Rest of North America Antibody Therapeutics Market by Disease Areas
10.2 Europe Antibody Therapeutics Market
10.2.1 Europe Antibody Therapeutics Market by Route of Administration
10.2.1.1 Europe Intravenous Market by Country
10.2.1.2 Europe Subcutaneous Market by Country
10.2.1.3 Europe Others Market by Country
10.2.2 Europe Antibody Therapeutics Market by Format
10.2.2.1 Europe Monoclonal Antibody Market by Country
10.2.2.2 Europe Polyclonal Antibody Therapy Market by Country
10.2.2.3 Europe Bispecific Antibody Market by Country
10.2.2.4 Europe Antibody fragment & Others Market by Country
10.2.3 Europe Antibody Therapeutics Market by Source
10.2.3.1 Europe Human Market by Country
10.2.3.2 Europe Humanized Market by Country
10.2.3.3 Europe Chimeric Market by Country
10.2.3.4 Europe Others Market by Country
10.2.4 Europe Antibody Therapeutics Market by End User
10.2.4.1 Europe Hospitals Market by Country
10.2.4.2 Europe Long-term care facilities Market by Country
10.2.4.3 Europe Others Market by Country
10.2.5 Europe Antibody Therapeutics Market by Disease Areas
10.2.5.1 Europe Autoimmune & Inflammatory Diseases Market by Country
10.2.5.2 Europe Neurology Market by Country
10.2.5.3 Europe Osteology Market by Country
10.2.5.4 Europe Hematology Market by Country
10.2.5.5 Europe Oncology Market by Country
10.2.5.6 Europe Infectious Diseases Market by Country
10.2.5.7 Europe Immunology Market by Country
10.2.5.8 Europe Others Market by Country
10.2.6 Europe Antibody Therapeutics Market by Country
10.2.6.1 Germany Antibody Therapeutics Market
10.2.6.1.1 Germany Antibody Therapeutics Market by Route of Administration
10.2.6.1.2 Germany Antibody Therapeutics Market by Format
10.2.6.1.3 Germany Antibody Therapeutics Market by Source
10.2.6.1.4 Germany Antibody Therapeutics Market by End User
10.2.6.1.5 Germany Antibody Therapeutics Market by Disease Areas
10.2.6.2 UK Antibody Therapeutics Market
10.2.6.2.1 UK Antibody Therapeutics Market by Route of Administration
10.2.6.2.2 UK Antibody Therapeutics Market by Format
10.2.6.2.3 UK Antibody Therapeutics Market by Source
10.2.6.2.4 UK Antibody Therapeutics Market by End User
10.2.6.2.5 UK Antibody Therapeutics Market by Disease Areas
10.2.6.3 France Antibody Therapeutics Market
10.2.6.3.1 France Antibody Therapeutics Market by Route of Administration
10.2.6.3.2 France Antibody Therapeutics Market by Format
10.2.6.3.3 France Antibody Therapeutics Market by Source
10.2.6.3.4 France Antibody Therapeutics Market by End User
10.2.6.3.5 France Antibody Therapeutics Market by Disease Areas
10.2.6.4 Russia Antibody Therapeutics Market
10.2.6.4.1 Russia Antibody Therapeutics Market by Route of Administration
10.2.6.4.2 Russia Antibody Therapeutics Market by Format
10.2.6.4.3 Russia Antibody Therapeutics Market by Source
10.2.6.4.4 Russia Antibody Therapeutics Market by End User
10.2.6.4.5 Russia Antibody Therapeutics Market by Disease Areas
10.2.6.5 Spain Antibody Therapeutics Market
10.2.6.5.1 Spain Antibody Therapeutics Market by Route of Administration
10.2.6.5.2 Spain Antibody Therapeutics Market by Format
10.2.6.5.3 Spain Antibody Therapeutics Market by Source
10.2.6.5.4 Spain Antibody Therapeutics Market by End User
10.2.6.5.5 Spain Antibody Therapeutics Market by Disease Areas
10.2.6.6 Italy Antibody Therapeutics Market
10.2.6.6.1 Italy Antibody Therapeutics Market by Route of Administration
10.2.6.6.2 Italy Antibody Therapeutics Market by Format
10.2.6.6.3 Italy Antibody Therapeutics Market by Source
10.2.6.6.4 Italy Antibody Therapeutics Market by End User
10.2.6.6.5 Italy Antibody Therapeutics Market by Disease Areas
10.2.6.7 Rest of Europe Antibody Therapeutics Market
10.2.6.7.1 Rest of Europe Antibody Therapeutics Market by Route of Administration
10.2.6.7.2 Rest of Europe Antibody Therapeutics Market by Format
10.2.6.7.3 Rest of Europe Antibody Therapeutics Market by Source
10.2.6.7.4 Rest of Europe Antibody Therapeutics Market by End User
10.2.6.7.5 Rest of Europe Antibody Therapeutics Market by Disease Areas
10.3 Asia Pacific Antibody Therapeutics Market
10.3.1 Asia Pacific Antibody Therapeutics Market by Route of Administration
10.3.1.1 Asia Pacific Intravenous Market by Country
10.3.1.2 Asia Pacific Subcutaneous Market by Country
10.3.1.3 Asia Pacific Others Market by Country
10.3.2 Asia Pacific Antibody Therapeutics Market by Format
10.3.2.1 Asia Pacific Monoclonal Antibody Market by Country
10.3.2.2 Asia Pacific Polyclonal Antibody Therapy Market by Country
10.3.2.3 Asia Pacific Bispecific Antibody Market by Country
10.3.2.4 Asia Pacific Antibody fragment & Others Market by Country
10.3.3 Asia Pacific Antibody Therapeutics Market by Source
10.3.3.1 Asia Pacific Human Market by Country
10.3.3.2 Asia Pacific Humanized Market by Country
10.3.3.3 Asia Pacific Chimeric Market by Country
10.3.3.4 Asia Pacific Others Market by Country
10.3.4 Asia Pacific Antibody Therapeutics Market by End User
10.3.4.1 Asia Pacific Hospitals Market by Country
10.3.4.2 Asia Pacific Long-term care facilities Market by Country
10.3.4.3 Asia Pacific Others Market by Country
10.3.5 Asia Pacific Antibody Therapeutics Market by Disease Areas
10.3.5.1 Asia Pacific Autoimmune & Inflammatory Diseases Market by Country
10.3.5.2 Asia Pacific Neurology Market by Country
10.3.5.3 Asia Pacific Osteology Market by Country
10.3.5.4 Asia Pacific Hematology Market by Country
10.3.5.5 Asia Pacific Oncology Market by Country
10.3.5.6 Asia Pacific Infectious Diseases Market by Country
10.3.5.7 Asia Pacific Immunology Market by Country
10.3.5.8 Asia Pacific Others Market by Country
10.3.6 Asia Pacific Antibody Therapeutics Market by Country
10.3.6.1 China Antibody Therapeutics Market
10.3.6.1.1 China Antibody Therapeutics Market by Route of Administration
10.3.6.1.2 China Antibody Therapeutics Market by Format
10.3.6.1.3 China Antibody Therapeutics Market by Source
10.3.6.1.4 China Antibody Therapeutics Market by End User
10.3.6.1.5 China Antibody Therapeutics Market by Disease Areas
10.3.6.2 Japan Antibody Therapeutics Market
10.3.6.2.1 Japan Antibody Therapeutics Market by Route of Administration
10.3.6.2.2 Japan Antibody Therapeutics Market by Format
10.3.6.2.3 Japan Antibody Therapeutics Market by Source
10.3.6.2.4 Japan Antibody Therapeutics Market by End User
10.3.6.2.5 Japan Antibody Therapeutics Market by Disease Areas
10.3.6.3 India Antibody Therapeutics Market
10.3.6.3.1 India Antibody Therapeutics Market by Route of Administration
10.3.6.3.2 India Antibody Therapeutics Market by Format
10.3.6.3.3 India Antibody Therapeutics Market by Source
10.3.6.3.4 India Antibody Therapeutics Market by End User
10.3.6.3.5 India Antibody Therapeutics Market by Disease Areas
10.3.6.4 South Korea Antibody Therapeutics Market
10.3.6.4.1 South Korea Antibody Therapeutics Market by Route of Administration
10.3.6.4.2 South Korea Antibody Therapeutics Market by Format
10.3.6.4.3 South Korea Antibody Therapeutics Market by Source
10.3.6.4.4 South Korea Antibody Therapeutics Market by End User
10.3.6.4.5 South Korea Antibody Therapeutics Market by Disease Areas
10.3.6.5 Singapore Antibody Therapeutics Market
10.3.6.5.1 Singapore Antibody Therapeutics Market by Route of Administration
10.3.6.5.2 Singapore Antibody Therapeutics Market by Format
10.3.6.5.3 Singapore Antibody Therapeutics Market by Source
10.3.6.5.4 Singapore Antibody Therapeutics Market by End User
10.3.6.5.5 Singapore Antibody Therapeutics Market by Disease Areas
10.3.6.6 Malaysia Antibody Therapeutics Market
10.3.6.6.1 Malaysia Antibody Therapeutics Market by Route of Administration
10.3.6.6.2 Malaysia Antibody Therapeutics Market by Format
10.3.6.6.3 Malaysia Antibody Therapeutics Market by Source
10.3.6.6.4 Malaysia Antibody Therapeutics Market by End User
10.3.6.6.5 Malaysia Antibody Therapeutics Market by Disease Areas
10.3.6.7 Rest of Asia Pacific Antibody Therapeutics Market
10.3.6.7.1 Rest of Asia Pacific Antibody Therapeutics Market by Route of Administration
10.3.6.7.2 Rest of Asia Pacific Antibody Therapeutics Market by Format
10.3.6.7.3 Rest of Asia Pacific Antibody Therapeutics Market by Source
10.3.6.7.4 Rest of Asia Pacific Antibody Therapeutics Market by End User
10.3.6.7.5 Rest of Asia Pacific Antibody Therapeutics Market by Disease Areas
10.4 LAMEA Antibody Therapeutics Market
10.4.1 LAMEA Antibody Therapeutics Market by Route of Administration
10.4.1.1 LAMEA Intravenous Market by Country
10.4.1.2 LAMEA Subcutaneous Market by Country
10.4.1.3 LAMEA Others Market by Country
10.4.2 LAMEA Antibody Therapeutics Market by Format
10.4.2.1 LAMEA Monoclonal Antibody Market by Country
10.4.2.2 LAMEA Polyclonal Antibody Therapy Market by Country
10.4.2.3 LAMEA Bispecific Antibody Market by Country
10.4.2.4 LAMEA Antibody fragment & Others Market by Country
10.4.3 LAMEA Antibody Therapeutics Market by Source
10.4.3.1 LAMEA Human Market by Country
10.4.3.2 LAMEA Humanized Market by Country
10.4.3.3 LAMEA Chimeric Market by Country
10.4.3.4 LAMEA Others Market by Country
10.4.4 LAMEA Antibody Therapeutics Market by End User
10.4.4.1 LAMEA Hospitals Market by Country
10.4.4.2 LAMEA Long-term care facilities Market by Country
10.4.4.3 LAMEA Others Market by Country
10.4.5 LAMEA Antibody Therapeutics Market by Disease Areas
10.4.5.1 LAMEA Autoimmune & Inflammatory Diseases Market by Country
10.4.5.2 LAMEA Neurology Market by Country
10.4.5.3 LAMEA Osteology Market by Country
10.4.5.4 LAMEA Hematology Market by Country
10.4.5.5 LAMEA Oncology Market by Country
10.4.5.6 LAMEA Infectious Diseases Market by Country
10.4.5.7 LAMEA Immunology Market by Country
10.4.5.8 LAMEA Others Market by Country
10.4.6 LAMEA Antibody Therapeutics Market by Country
10.4.6.1 Brazil Antibody Therapeutics Market
10.4.6.1.1 Brazil Antibody Therapeutics Market by Route of Administration
10.4.6.1.2 Brazil Antibody Therapeutics Market by Format
10.4.6.1.3 Brazil Antibody Therapeutics Market by Source
10.4.6.1.4 Brazil Antibody Therapeutics Market by End User
10.4.6.1.5 Brazil Antibody Therapeutics Market by Disease Areas
10.4.6.2 Argentina Antibody Therapeutics Market
10.4.6.2.1 Argentina Antibody Therapeutics Market by Route of Administration
10.4.6.2.2 Argentina Antibody Therapeutics Market by Format
10.4.6.2.3 Argentina Antibody Therapeutics Market by Source
10.4.6.2.4 Argentina Antibody Therapeutics Market by End User
10.4.6.2.5 Argentina Antibody Therapeutics Market by Disease Areas
10.4.6.3 UAE Antibody Therapeutics Market
10.4.6.3.1 UAE Antibody Therapeutics Market by Route of Administration
10.4.6.3.2 UAE Antibody Therapeutics Market by Format
10.4.6.3.3 UAE Antibody Therapeutics Market by Source
10.4.6.3.4 UAE Antibody Therapeutics Market by End User
10.4.6.3.5 UAE Antibody Therapeutics Market by Disease Areas
10.4.6.4 Saudi Arabia Antibody Therapeutics Market
10.4.6.4.1 Saudi Arabia Antibody Therapeutics Market by Route of Administration
10.4.6.4.2 Saudi Arabia Antibody Therapeutics Market by Format
10.4.6.4.3 Saudi Arabia Antibody Therapeutics Market by Source
10.4.6.4.4 Saudi Arabia Antibody Therapeutics Market by End User
10.4.6.4.5 Saudi Arabia Antibody Therapeutics Market by Disease Areas
10.4.6.5 South Africa Antibody Therapeutics Market
10.4.6.5.1 South Africa Antibody Therapeutics Market by Route of Administration
10.4.6.5.2 South Africa Antibody Therapeutics Market by Format
10.4.6.5.3 South Africa Antibody Therapeutics Market by Source
10.4.6.5.4 South Africa Antibody Therapeutics Market by End User
10.4.6.5.5 South Africa Antibody Therapeutics Market by Disease Areas
10.4.6.6 Nigeria Antibody Therapeutics Market
10.4.6.6.1 Nigeria Antibody Therapeutics Market by Route of Administration
10.4.6.6.2 Nigeria Antibody Therapeutics Market by Format
10.4.6.6.3 Nigeria Antibody Therapeutics Market by Source
10.4.6.6.4 Nigeria Antibody Therapeutics Market by End User
10.4.6.6.5 Nigeria Antibody Therapeutics Market by Disease Areas
10.4.6.7 Rest of LAMEA Antibody Therapeutics Market
10.4.6.7.1 Rest of LAMEA Antibody Therapeutics Market by Route of Administration
10.4.6.7.2 Rest of LAMEA Antibody Therapeutics Market by Format
10.4.6.7.3 Rest of LAMEA Antibody Therapeutics Market by Source
10.4.6.7.4 Rest of LAMEA Antibody Therapeutics Market by End User
10.4.6.7.5 Rest of LAMEA Antibody Therapeutics Market by Disease Areas
Chapter 11. Company Profiles
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.1.2 Financial Analysis
11.1.3 Segmental and Regional Analysis
11.1.4 Research & Development Expense
11.1.5 Recent strategies and developments:
11.1.5.1 Partnerships, Collaborations, and Agreements:
11.1.5.2 Product Launches and Product Expansions:
11.1.6 SWOT Analysis
11.2 AbbVie, Inc.
11.2.1 Company Overview
11.2.2 Financial Analysis
11.2.3 Regional Analysis
11.2.4 Research & Development Expense
11.2.5 Recent strategies and developments:
11.2.5.1 Partnerships, Collaborations, and Agreements:
11.2.5.2 Acquisition and Mergers:
11.2.6 SWOT Analysis
11.3 Johnson & Johnson (Johnson & Johnson Services, Inc.)
11.3.1 Company Overview
11.3.2 Financial Analysis
11.3.3 Segmental &Regional Analysis
11.3.4 Research & Development Expenses
11.3.5 Recent strategies and developments:
11.3.5.1 Partnerships, Collaborations, and Agreements:
11.3.6 SWOT Analysis
11.4 Merck KGaA
11.4.1 Company Overview
11.4.2 Financial Analysis
11.4.3 Segmental and Regional Analysis
11.4.4 Research & Development Expense
11.4.5 Recent strategies and developments:
11.4.5.1 Partnerships, Collaborations, and Agreements:
11.4.6 SWOT Analysis
11.5 Bristol Myers Squibb Company
11.5.1 Company Overview
11.5.2 Financial Analysis
11.5.3 Regional Analysis
11.5.4 Research & Development Expenses
11.5.5 Recent strategies and developments:
11.5.5.1 Acquisition and Mergers:
11.5.6 SWOT Analysis
11.6 AstraZeneca PLC
11.6.1 Company Overview
11.6.2 Financial Analysis
11.6.3 Regional Analysis
11.6.4 Research & Development Expenses
11.6.5 SWOT Analysis
11.7 Sanofi S.A.
11.7.1 Company Overview
11.7.2 Financial Analysis
11.7.3 Segmental and Regional Analysis
11.7.4 Research & Development Expense
11.7.5 SWOT Analysis
11.8 Novartis AG
11.8.1 Company Overview
11.8.2 Financial Analysis
11.8.3 Segmental and Regional Analysis
11.8.4 Research & Development Expense
11.8.5 SWOT Analysis
11.9 Biogen, Inc.
11.9.1 Company Overview
11.9.2 Financial Analysis
11.9.3 Regional Analysis
11.9.4 Research & Development Expense
11.9.5 SWOT Analysis
11.10. Amgen, Inc.
11.10.1 Company Overview
11.10.2 Financial Analysis
11.10.3 Regional Analysis
11.10.4 Research & Development Expenses
11.10.5 SWOT Analysis
Chapter 12. Winning Imperative for Antibody Therapeutics Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings